Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zicronapine vs risperidone in schizophrenia (6‑month metabolic safety study)
2010-022181-28Phase 3Completed
- Sponsor
- Lundbeck
- Start
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of zicronapine in schizophrenia (2 arms), sponsored by Lundbeck. Primary endpoint: Metabolic parameters over 6 months. Started Dec 2010; status: completed.
02
Drugs
zicronapine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2010-022181-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022181-28.